The FDA has approved Eli Lilly’s Zepbound, a once-weekly injectable drug, for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Used in combination with a reduced-calorie diet and exercise, Zepbound can lead to improved sleep apnea and weight loss. The drug, initially developed for metabolic conditions, is the first FDA-approved therapy for sleep apnea, a condition that affects an estimated 25 million US adults and is usually managed with a medical breathing aid device.
US CISA unveils draft update to National Cyber Incident Response Plan – Dig Watch Updates
The US Cybersecurity and Infrastructure Security Agency (CISA) has released a draft update to the National Cyber Incident Response Plan. The plan aims to improve
